Neurocognitive Profiles and Predictors of Symptom Trajectory During and After Treatment in Adolescent Bulimia Nervosa.

Eur Eat Disord RevMay 14, 2026 (epub)
Clinical ResearchPsychiatryOpen access

Simar Singh, Franziska Plessow, Erin E Reilly et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial examined the relationship between neurocognitive profiles and treatment outcomes in 82 adolescents with bulimia nervosa (BN). The study found that while individual executive function measures did not predict outcomes, adolescents with lower overall performance on the Delis-Kaplan Executive Functioning System (D-KEFS) had a significantly higher frequency of self-induced vomiting post-treatment (p = 0.049).

Key findings

  • No individual executive function measures predicted treatment outcomes (all ps > 0.050).
  • K-means clustering identified two neurocognitive profiles based on D-KEFS performance.
  • Adolescents in the low-average D-KEFS performance cluster had a higher frequency of self-induced vomiting (p = 0.049).

Why it matters

Understanding neurocognitive profiles in adolescents with bulimia nervosa can enhance the prediction of treatment outcomes. This knowledge may guide clinicians in identifying patients at risk for poor outcomes and tailoring interventions accordingly.

Source

PubMed · PMID 42133874Free full text on PubMed Central

Published in Eur Eat Disord Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.